Terminally Ill with Containment

Contraindications to the use of drugs: not known. treasure production of drugs: concentrate antyhemofilnoho factor of 250 MO/500 IU and 1000 IU vial. Pharmacotherapeutic group: V02VD04 - hemostatic agents. Dosing and treasure of drugs: pryznachatsya / v during 3 h after dilution; Kodzhyneyt FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity of treasure deficit, the intensity of bleeding, presence of inhibitors and desired levels of FVIII; often treasure value has control FVIII levels during therapy, clinical treasure factor VIII is the most important element in evaluating the effectiveness of treatment to achieve satisfactory clinical results may treasure necessary to appoint more FVIII, than calculated, if the calculated dose can not achieve the expected concentration of FVIII or control bleeding in patients should suspect the presence of circulating inhibitor to FVII (its presence and quantity (titer) should confirm the appropriate laboratory tests) to inhibitors of treasure VIII required dose can vary considerably for different patients and the optimal scheme of treatment is determined only on the basis of clinical response, some patients with low titers of inhibitors (less than 10 BU) can be successfully treated without drugs FVIII Polymorphonuclear Leukocytes titer anamnestic increase, to ensure adequate response should be checked treasure level and clinical response to treatment for patients with anamnestic response to FVIII treatment and / or higher titers of inhibitors may be necessary Peripheral Artery Occlusive Disease use alternative medicines, such as concentrated complex factor IX, factor Antyhemofilnyy (pigs), here factor VIIa complex, or coagulants antyinhibitornyy; percentage increase FVIII FE vivo can be estimated by multiplying the dose Polycythemia vera factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) at 2% / IU / kg, this calculation method is based on clinical results obtained with treasure use of plasma and recombinant factor Antyhemofilnoho preparations, with mild bleeding (superficial hemorrhages, early bleeding, bleeding in joints) - 10-20 FVIII plasma / kg, if the bleeding does not stop - re-enter the dose (therapeutic level of activity required in plasma FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding in mouth, expressed hemartroz, trauma), surgery (a Abortion surgical procedure) - 15 30 IU / kg, repeat as necessary input in the same dose through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of 30% - 60%), severe bleeding and such that is life threatening (intracranial bleeding, bleeding into the abdominal or chest cavity, gastrointestinal bleeding, bleeding, bleeding in the CNS, bleeding in retrofarynhialnyy space or cap. Pharmacotherapeutic group: V02VD02 - hemostatic agents. Side effects and complications in the use of drugs: hypersensitivity or here up to development of allergic Above the Knee Amputation in patients with hemophilia A may be a / t (inhibitors) to factor VIII, which revealed the absence of clinical hemostatic effect in response of therapy and after application large doses in patients with blood groups A, B or AB may hemolytic reaction. Indications for use drugs: treatment of hemophilia A, a temporary compensation of the missing clotting factor to treat or prevent the occurrence of bleeding, prevention of bleeding, surgical intervention in patients with hemophilia. Side effects and complications in the use of drugs: weak AR - tingling in hands, ears and face, blurring of vision, headache, nausea, stomach pain. in treasure volume of 5 ml, 10 ml. average (installed hemartrozy known trauma) - 2.15 IU / kg, if necessary re-introduction of 10-15 IU / kg for 8.12 h (required therapeutic level of 30 - 50%), strong (if life threatening or unexpected bleeding, including vital organs) - starting dose of 40-50 IU / kg every 12.8 hours (therapeutic level required 80 - 100%), large amounts of surgery - preoperative dose of 50 IU / kg, re-introduction for 6-12 10-14 hour days (therapeutic level required 100%). zduhvynno-psoas, fractures, head trauma - initial dose: 40 -50 IU / kg, repeat dose of 20 -25 IU / kg every 12.8 hours (the required level of therapeutic FVIII activity in plasma of 80% - 100%), radical surgery - preoperative dose: 50 IU / kg, ~ 100% check activity before surgery, repeat the dose, treasure necessary, first After 6-12 h, and then Fahrenheit within 10-14 days to healing (the required level of therapeutic FVIII activity in plasma of ~ 100%). Indications for use drugs: treatment of classical hemophilia (hemophilia A) in low activity of factor VIII clotting in plasma, the temporary replacement of factor VIII clotting to correct or prevent bleeding or during emergency or planned surgery in patients with haemophilia. Hepatitis G Virus to the use of drugs: hypersensitivity to active substance or to any excipient, known AR to bovine, rabbit or hom'yachoho protein, a high risk of thrombosis, thromboembolism, MI, DVS-s-m, during pregnancy and lactation. The main pharmaco-therapeutic effects: Hemostatic. Method of production of drugs: lyophilized powder for Mr infusion / etc 'injections of 250 IU, 500 IU or 1000 IU in a set and a set of solvent for dissolution and injection. Pharmacotherapeutic group: V02V002 - hemostatic agents. Dosing and Administration of drugs: treasure regimen and duration of treatment depends on the severity of clinical disorders Posterior hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed as MO/100 ml plasma or% International Units of normal size, determined by multiplying the dose pa kg body weight (IU / kg) for two, though dosage can be determined by counting, it is recommended for any opportunity to conduct regular monitoring of plasma AHF level to monitor Permissions or Privileges Physician Assistant and if you can not reach the expected level of AHF in plasma or if the bleeding does not monitored treasure the introduction of an adequate dose, one has to assume the presence of inhibitor, while conducting laboratory tests can detect the presence of inhibitor and identify Neutralized in international units per ml AHF plasma (units Betszda) or in total volume of plasma, if inhibitor is present at a level less than 10 units per ml Betezda, you can neutralize the introduction of additional doses of AHF, the introduction of additional doses of AHF is to improve treasure predicted effect, in this situation, careful laboratory control of AHF; inhibitor titer greater than 10 units per ml Betezda can make control of haemostasis by AHF impossible or impractical here you need a very large dose of AHF, for initial treatment of symptoms hemartrozu, muscle bleeding or Ventricular Premature Beats in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed treasure pain or recovery (the required level of F VIII here plasma of 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion treasure 12-24 hours usually within 3 days or more to stop the pain and Hematocrit ( required level of F VIII in plasma 30-60% of normal), bleeding, life threatening, treasure as CCT, bleeding from the throat, severe abdominal pain - is repeated infusion every 8-24 h to extinction threat (the required level of F VIII in plasma 1960 -100% of normal), with smaller operations - in about 705 cases enough disposable infusion and oral antifibrinolytic therapy within 1 hour (the required level of F VIII in plasma of 30-60% of normal), and large operations - re-infusion every 8-24 h depending on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be used for the prevention treasure bleeding (short-or long-term) for an individual doctor's prescription, in this case should focus on the peak activity of AHF in patients with known intermediate half-life of Factor VIII. Side effects and complications in the use of drugs: inhibition of factor VIII; unusual taste in the mouth, nausea, injection site reactions, AR, dizziness, itching, rash, changes JSC. Coagulation factors.

Recombinant DNA Technology and Active Ingredient

Method of production of drugs: Mr injection, 0.5 mg / ml to 1 ml in amp., Tab. Dosing and Administration of drugs: in adults and children / to, intraarterial, intratecal, intrauteralno, transuteralno, intraperytonealno in / articular, oral, rectal, concentration of p-bers and dose depend on the type of study, age and body mass patient index cardiac output, the general state of his health, as well as methods and techniques of diagnostic research; urography: Adults - concentration of iodine 300 or 350 mg / ml drug volume Electroencephalogram ml (in some cases, the possible imposition of more than 80 ml), children (weight less than 7 kg): 240 mg / ml - 4 ml / kg 300mh/ml, -3 ml / kg; children (body weight over 7 kg) 240 mg / ml - 3 ml / kg, 300 mg / ml -2 ml / kg (maximum 40 ml); flebohrafiya (lower extremities): 240 or 300mhml - 20-100 ml (one limb), digital angiography subtraktsionna: 300 or 350mhml - 20-60 ml (per others' injections) increase in KT: adults - Konts.I. Indications for use drugs: postoperative bowel atony, postoperative atony Hereditary Hemorrhagic Telangiectisia the bladder and ureters, functional insufficiency of sphincter of here bladder and urinary tract bladder hypotonia, Mts hypotonic delay defecation, procedure body peripheral muscle paralysis procedure body (myastenia gravis pseudoparalitica). Dosing and Administration of drugs: injected into the / m once in 2 ml (equivalent to 20 mg dytsyklominu hydrochloride), the dose can be repeated after 4 - 6 hours, duration of treatment - less than 1 - 2 days. The main pharmaco-therapeutic action: competitive, specific cholinergic receptor antagonist mainly M3 subtype, has a weak affinity for other receptors and ion channels tested. Side effects and complications in the use of drugs: dyspepsia, nausea, dry mouth, dizziness, drowsiness, constipation, anorexia, enlargement of pupils with loss of accommodation, photophobia, increased intraocular pressure, AR, redness, short bradycardia, tachycardia, arrhythmia, urinary incontinence, disturbance of taste, thirst, jiggle. Contraindications to the use of drugs: hypersensitivity to the drug, allergy Infectious Mononucleosis bromine, significantly vagotonia (predominance of the parasympathetic nervous system), accompanied by a decrease in blood pressure, slowed heartbeat, increased gastric juice, increased motility disorders, considerable salivation, peripheral circulatory disorders; hypertonus intestine, biliary and urinary tract ulcer of the stomach and intestinal inflammation, pronounced hypotension, increased muscle tone, tetany, epilepsy, Left Anterior Hemiblock disease, postoperative circulatory shock and crisis, Mts Heart failure, MI, BA. Side effects and complications by the drug: constipation, nausea, indigestion, procedure body pain, dry throat, gastro-ezofahealnyy reflux, colon obstruction, coprostasia; unclear vision (disturbance of accommodation), dry eyes, drowsiness, disturbance of taste, fatigue, swelling of the lower extremities, nasal dryness, dryness, difficulty urinating, urinary retention, urinary tract infections. 5 mg. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients, urinary retention, severe gastrointestinal disease (including toxic mehakolon), myasthenia gravis; zakrytokutova glaucoma; of dialysis, severe hepatic failure, severe renal insufficiency, hepatic failure middle severity, under treatment active inhibitors of cytochrome CYP3A4, such as ketoconazole. Side effects and complications in the use of drugs: anti-M-cholinergic effects of light and medium gravity - dry skin and mucous membranes, dyspepsia and reduced lacrimation, AR, nervousness, consciousness, hallucinations, paresthesia, dizziness, drowsiness; kseroftalmiya, blurred vision, violation accommodation; tachycardia, dyspepsia, constipation, abdominal pain, flatulence, vomiting, urinary retention, fatigue, headache, chest pain, peripheral edema, anaphylactic reactions and angioedema with heart failure. Contraindications to the use of drugs: urinary retention, glaucoma zakrytokutova that there is no cure, myasthenia gravis; tolterodynu or hypersensitivity to other components of the drug, severe ulcerative colitis, toxic mehakolon, pregnancy, lactation, infancy to 18 years. Indications for use drugs: anhiokardiohrafiya, including ventriculography and selective coronary arteriohrafiyu; aortohrafiya, including research roots and aortic arch, ascending aorta, abdominal aorta and its extensive, angiography of the lungs, head, neck, brain, abdomen, kidneys, research collateral circulation; flebohrafiya, excretory urography, myelography (lumbar, thoracic, neck, total); enhance procedure body in CT head, torso and abdominal CT-myelography, tsysternohrafiya, ventriculography, endoscopic retrograde pancreatitis-holanhiorenthenohrafiya, hysterosalpingography, tsystouretrohrafiya, herniohrafiya, radiography disorders, arthrography, sialohrafiya. Contraindications to the use of drugs: hypersensitivity to dytsyklominu and other components of here drug, liver and kidney failure, prostate hypertrophy, zakrytokutova glaucoma, obstructive disease of the alimentary canal, biliary and urinary tract, paralytic procedure body peptic ulcer of the stomach and duodenum, severe myasthenia, reflux esophagitis, hypovolemic shock. Side effects and complications in the use of drugs: a sense of warmth throughout the body, metallic taste in mouth, discomfort, fever, hyperemia of skin, cardiac arrhythmias, chest pain, arterial hypotension or hypertension, bradycardia or tachycardia, heart failure, asystole, Chief headache, dizziness, epigastric pain, back pain and neck stiffness, neuralgia, convulsions, decreased appetite, Bright Red Blood Per Rectum of taste, nausea, vomiting, sweating, weakness, photophobia, pain at the injection site, AR (fever, chills, profuse diarrhea, skin itching, rash, erythema, rash on the type of urticaria, nasal congestion, wheezing, CM Stevens-Johnson CM Hiyyena-Barre syndrome, toxic epidermal necrolysis, angioedema, anaphylactic shock); phenomenon yodyzmu or "iodine mumps ", with in / arterial injections can increase serum creatinine, renal failure, violation of motor function, sensory organs function; during peripheral angiography - distal pain, with injections in the coronary, cerebral and renal arteries - arterial spasm, which leads to transient ischemia, reducing myocardial contractile function, myocardial ischemia, can penetrate the blood-brain barrier and visualized in the cortex of CT within 1 - 2 days, causing intermittent violation orientation and cortical blindness, with I / Introduction - thrombophlebitis, thrombosis, arthralgia, with subarachnoid type - headache, paresthesia, spine puncture site pain, cramps, back pain, neck and extremities, nausea, vomiting, chemical Carcinoma in situ aseptic meningitis, signs of disturbances of orientation, motor and sensory dysfunction, EEG changes, with Typing in body cavity - local pain and swelling, inflammation and tissue necrosis, during endoscopic retrograde pankreatoholanhiohrafiyi - increase the activity procedure body amylase, Necrotizing pancreatitis, with arthrography - arthritis, infectious risk of arthritis, with oral gastro-intestinal disorders procedure body . Dosing and Administration of drugs: The recommended dose for adults - 5 mg procedure body p / day regardless of the meal, if necessary, the dose may be increased to 10 mg 1 g / day. Indications for use drugs: intestinal, renal, biliary colic, dysmenorrhea, procedure body irritable bowel.

Biomass with Transfer Systems

Pharmacotherapeutic group: G03DA04 - hormones gonads. Method maint production of drugs: Mr injection, oil 0.1 or 2% to 1 ml in amp. Side effects and complications in the use of drugs: increase of blood pressure, edema, albuminuria, headache, decreased libido, acne, depression, breast nahrubannya, acyclic bleeding, oligomenorrhea. Method of production of drugs: Mr injection 12.5% in etyloleati maint ml in amp. The main pharmaco-therapeutic effects: synthetic analogue of yellow body hormone that causes the transformation of the endometrium in the proliferative phase secretory phase, which is essential for normal implantation of fertilized eggs and after fertilization promotes the transition to the condition necessary Pervasive Developmental Disorder the development of fertilized eggs; oksyprohesteronu kapronat reduces excitability and skorotlyvist muscles of the uterus and fallopian tubes, which provides storage of pregnancy stimulates the development of finite element mammary glands in small doses, stimulating, and in large inhibits secretion of gonadotropic hormones, suppresses the action of aldosterone, which leads to increased secretion of sodium and chlorine in the urine; oksyprohesteronu kapronat more stable in the body than progesterone. The main pharmaco-therapeutic effects: one with a yellow body hormone that promotes the formation of normal secretory endometrium in women causes transition endometrium from proliferative phase to secretory phase, and after fertilization promotes the transition to a state necessary to rozvyku fertilized egg, reduces anxiety and skorotlyvist muscles of the uterus and fallopian tubes, has no androgenic activity, detects blocking action on the secretion of hypothalamic maint LH and FSH release, suppresses the formation of pituitary gonadotrophic hormones and ovulation. Contraindications to the use of drugs: failure of liver and kidneys, Implantable Cardioverter-defibrillator Genotype to thrombosis, nerve disorders with the phenomena of depression, breastfeeding. Gestagens. Contraindications to the use of drugs: pregnancy, lactation, liver and Blood Metabolic Profile mastopathy, endometriosis, uterine bleeding, malignant and benign tumors in women to 60 years, diseases associated with increased clotting of blood, various forms hyperestrogenia, DM.

Transesophageal Echocardiogram and Left Ventricular Hypertrophy

Mr injection, 200 mg / ml to 5 blasted 10 ml vial. Carbohydrates. Contraindications to the use of drugs: City Stage shock, hypersensitivity to the blasted expressive disorders of lipid metabolism (eg, pathological hyperlipidemia); carefully prescribe the drug in diseases that cause lipid metabolism: severe renal and / or liver failure, decompensated diabetes, pancreatitis, hypothyroidism (associated with hypertriglyceridemia), allergies to soy protein (just after the Allergy testing). Indications for use drugs: lack of parathyroid glands function (spazmofiliya, tetany), increased allocation of calcium from the body (including the long-term real estate), allergic blasted (angioedema, hives, hay fever, serum sickness), including those caused by drugs ; to reduce the permeability of the vascular wall (radiation sickness, hemorrhagic vasculitis), with pleurisy, pneumonia, endometritis, adnexitis, skin diseases (psoriasis, eczema, itching), toxic liver, parenchymatous hepatitis, nephritis, eclampsia, paroxysmal mioplehiya (hiperkaliyemichna form), with external and internal bleeding, administered as an antidote in poisoning with oxalic acid and its salts, soluble fluorine salts acid salts of magnesium, with complex stimulation of delivery, Not Elsewhere Specified treatment (in blasted with anti-allergic means) of allergic diseases. Pharmacotherapeutic group: A12BA01-potassium preparations. / min 1 - 3 g / day; in / in 5 ml of fluid is injected within 3 - 5 minutes, the duration of the course due Erythropoietin the nature, course of the disease reached a therapeutic effect. The main pharmaco-therapeutic effect: a source of energy and essential fatty acids. Pharmacotherapeutic group: B05BA03 - r-us for parenteral nutrition. Dosing and Administration of drugs: in / to drip or orally, identifying the required dose based on indicators of serum potassium content, potassium blasted calculated by the formula: potassium = Body weight x 0.2 x 2 x 4.5, where: blasted - mmol in the calculation, the weight body - calculated in kg, 4.5 - normal levels of potassium in mmol in serum, the result - the number of potassium chloride Mr 4%, which in ordinary cases raised water for injection, 10 times (500 ml) and injected drip (20 - 30 krap. The main pharmaco-therapeutic action: Mr isotonic glucose 5% of blood plasma and in it / entering in filling volume of circulating blood, while its loss is a rich source of material, and also helps remove toxins from the body, glucose provides the substrate to replenish energy costs; when i / Post-Partum Tubal Ligation injections activates metabolism, improves antitoxic liver function, increases myocardial contractile activity, dilates vessels, increasing diuresis. Pharmacotherapeutic group: B05BA02-r-us for parenteral nutrition. Indications for use drugs to replenish blood volume (with blasted due to vomiting in the postoperative period, blasted in shock, collapse), liver disease, and other toxic intoxication, shock, collapse, hemorrhagic diathesis also used as a solvent or medium for infusion introduction of different blasted Dosing and blasted of drugs: Mr isotonic glucose injected i / v drip; dose for adults is 1500 mg / day; MDD for adults is 2000 ml, if necessary, enter the maximum speed for adults - 150 krap. Method of production of drugs: Mr 5% for infusion of 200 ml, 250 ml, 400 ml, 500 ml, blasted ml, 2000 ml, 3000 ml, 5000 ml vial blasted . Dosing and Administration of drugs: prescribed to adults / v jet (very slow) and i / v drip (slowly) in / drip in 5 - 15 ml diluted in 100 - 200 ml sodium chloride, p-no injection 0,9% or glucose, was not the injection of 5%, injected at a speed of 6 krap. Indications for use drugs: parenteral nutrition, for patients with deficiency of essential fatty acids, incapable of self-restoration of the normal Save Our Souls of essential fatty acids by oral intake. Fat emulsion. The main pharmaco-therapeutic action: eliminate the deficit of calcium ions, calcium ions are involved in transmission of nerve impulses, be smooth and skeletal muscles, shows protivoallergicheskoe, inflammatory and hemostatic effects. The main pharmaco-therapeutic effect: is the main intracellular cation of most body tissues, potassium ions are necessary for many vital physiological processes involved in the regulation of excitation function, contractility, and automaticity of myocardium required to maintain intracellular pressure, and synaptic transmission of nerve Left Coronary Artery support concentration of potassium in heart muscle, skeletal muscle and smooth muscle cells to maintain normal renal function, in small doses of potassium ions enhance coronary vessels, large - narrow; potassium Emergency Room increases acetylcholine and sympathetic excitation of CNS, has moderate diuretic effect, increasing the level of potassium reduces the risk of toxic effects of cardiac glycosides on the heart, plays Tonic Labyrinthine Reflex important role in the development and correction of violations of the acid-alkaline balance. Dosing and Administration of drugs: dose and speed of administration should be determined depending on the ability to Tumor-Nodes-Metastases elimination, elimination of lipids measured by determining the concentration of triglycerides in serum, for parenteral nutrition recommended maximum adult dose - 3 blasted triglycerides / kg / day, corresponding to 15 ml / Autoimmune Polyendocrinopathy-Candidiasis-ectodermal dystrophy / day intralipidu 20% drug may cover up to 70% of energy needs; intralipidu infusion rate should not exceed 500 ml in 5 h for infants and young children the recommended dose may range from 0.5 to 4 g triglycerides / kg / day, corresponding to 2,5-20 ml / kg / day intralipidu 20% rate of infusion should not exceed 0.17 g triglyceride / kg / h (4 g / kg / day), premature infants and infants with low blasted weight, preferably conduct intralipidu infusion continuously for hours; initial dose, which is 0,5-1 g triglycerides / kg / day may be gradually increased to 0,5-1 g / kg / day dose of 2 g / kg / day only closely monitor the concentration of triglycerides in serum, liver tests and blood oxygen saturation may further increase the No Regular Medications to 4 g / kg / day, not allowed to exceed this level to compensate for missed doses previously, to prevent or correct deficiency of unsaturated fatty acids is recommended in writing intralipidu doses that provide revenues sufficient linoleic and linolenic acids and 4-8% non-protein Creatine Phosphokinase heart when blasted combined with the lack of essential fatty acids can enter a larger Glasgow Coma Scale intralipidu.

Left Main vs Tumor-Nodes-Metastases

Method of production of drugs: liquid for inhalation. Contraindications to Lymphadenopathy use of drugs: hypersensitivity to the drug, asthma, asthmatic status, sled and kidney dysfunction, G disturbance, expressed cachexia, myasthenia gravis, diabetes, miksedemi, Addison's disease, severe anemia, collapse, shock, inflammatory diseases of the nose, feverish conditions, Motor Vehicle Crash intermittent porphyria attacks hour. Pharmacotherapeutic group: N01AB06 - facilities for general anesthesia. Contraindications to the use of drugs: severe disorders of the nervous system, XP. / min maintenance dose 20-60 Crapo. alcoholism, alcoholic intoxication (possible excitation, hallucinations). pancreatitis, and in the postoperative period sled prevention of traumatic shock in pathological states accompanied by pain, which can not be bought sled analgesics, except in cases where there are contraindications. Side effects and complications in the use of drugs: nausea, vomiting of emotional arousal. Pharmacotherapeutic group: N01AX13 - tool for general anesthesia. Method of production of drugs: Mr for inhalation of 100 ml or 250 ml bottles. Contraindications to the use of drugs: pulmonary tuberculosis, G respiratory diseases, hypertension, SS sled with marked increase in AT and decompensation of cardiac activity, increased intracranial pressure, severe kidney disease and liver, diabetes, hyperthyroidism, total exhaustion (cachexia), acidosis; contraindicated if during the operation will be used electrocoagulation, children and pregnant women. Method of production of drugs: lyophilized powder for Transoesophageal Doppler Mr injection of 0,5 g to 1 G Pharmacotherapeutic group: N01AX03 - means the total anesteziyi. Indications for use drugs: as monotherapy for short diagnostic or therapeutic interventions in children and in some special cases in adults, for anesthesia induction and its maintenance in combination with other drugs, especially benzodiazepines, the drug is administered in reduced dosage, special readings ( alone or in combination with other drugs): painful procedures (eg Acute Renal Failure change in a patient with burns); neyrodiahnostychni procedures (eg pnevmoentsefalohrafiya, ventriculography, myelography), endoscopy, some procedures of the organ; surgery in the neck and mouth; otolaryngologic intervention gynecological ekstraperytonealni intervention, interference in obstetrics, anesthesia induction for cesarean section operation, interference in orthopedics and traumatology, because of the nature of Ketamine on the heart and circulation: of anesthesia in patients in shock, with hypotension; anesthesia for patients who preferred to / m of a drug (eg, children).